Dermal Physiologically-Based Pharmacokinetic (PBPK) Models Accounting for the Absorption and Evaporation of Vehicle/Co-Solvent Following the Application of Generic Dermatological Products

0
122

Opportunity ID: 330003
Opportunity Number: FOR-FD-20-027
Opportunity Title: Dermal Physiologically-Based Pharmacokinetic (PBPK) Models Accounting for the Absorption and Evaporation of Vehicle/Co-Solvent Following the Application of Generic Dermatological Products
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Agriculture
Consumer Protection
Food and Nutrition
Category Explanation:
CFDA Number(s): 93.103
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Additional Information on Eligibility:
Agency Code: HHS-FDA
Agency Name: Department of Health and Human Services
Food and Drug Administration
Posted Date: Nov 23, 2020
Last Updated Date: Nov 23, 2020
Estimated Synopsis Post Date:
Fiscal Year: 2021
Award Ceiling:
Award Floor:
Estimated Total Program Funding:
Expected Number of Awards:
Description: The overall objective of this funding opportunity is to develop an enhanced mechanistic PBPK model for generic dermatological drug products by accounting for the absorption and evaporation of vehicle/co-solvent simultaneously and implementing the effect of these two dynamic processes on the permeation of a drug molecule through skin. The developed model will be utilized to inform decisions on generic dermatological product development, to enhance the understanding of the effect of metamorphosis of dermatological drug products on skin absorption, and to predict the local and systemic exposure of a drug molecule following topical application of dermatological drug products.
Version: 1





Visit the Official Webpage For More Details on Dermal Physiologically-Based Pharmacokinetic (PBPK) Models Accounting for the Absorption and Evaporation of Vehicle/Co-Solvent Following the Application of Generic Dermatological Products

LEAVE A REPLY

Please enter your comment!
Please enter your name here